Current Studies

Fenzian
Technical Title:  Effect of Fenzian™ Treatment on Symptoms, Pulmonary Function and Albuterol/Salbutamol Use in Patients with Mild to Moderate Persistent Asthma: A Multicenter, Sham-Controlled Clinical Trial

Ardian
Renal Denervation in Patients with Uncontrolled Hypertension

Daiichi Sankyo - ENGAGE-AF
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin In Subjects with Atrial Fibrillation – Effective aNticoaGulation with Factor xA Next GEneration in Atrial Fibrillation (ENGAGE AF – TIMI 48)

Novartis – COPD
CQAB149B2348: A phase IIIb multicentre,52-week treatment, randomised, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150µg o.d. vs inhaled tiotropium 18µg o.d. on lung function, rate of exacerbations and related outcomes in patients with COPD (Chronic Obstructive Pulmonary Disease, sometimes known as chronic bronchitis and emphysema, or Chronic Airflow Limitation).

Roche ACS
A phase III, double-blind, randomised placebo controlled study to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)

Beetroot juice – hypertension
The effect of beetroot juice on circulating nitrate and nitrite levels and blood pressure in normotensives and hypertensives.

Pathway studies - for patients with hypertension
Optimal treatment for drug resistant hypertension.  These studies are kindly supported by the British Heart Foundation.

Accelerate
A randomised, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk of cardiovascular and renal events, aliskiren, on top of conventional treatment, reduces cardiovascular and renal morbidity and mortality.

Lundbeck Nalmefene - Alcohol reduction study
A 52 –week, randomized, double-blind, placebo-controlled, parallel-group, safety and tolerability study of nalmefene, as needed use, in patients with alcohol dependence.

GSK2 – Hypertension
A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis.